Financialsexperimental

ACRO BIOMEDICAL CO., LTD. (ACBM). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.

Income Statement Balance Sheet Cash FlowQuarterly Annual

USD (whole amounts) · shares (whole numbers) · per-share amounts in USD

Income Statement	Q2 FY26 30 Jun 2026	Q1 FY26 31 Mar 2026	Q4 FY25 31 Dec 2025	Q3 FY25 30 Sept 2025	Q2 FY25 30 Jun 2025	Q1 FY25 31 Mar 2025	Q4 FY24 31 Dec 2024	Q3 FY24 30 Sept 2024	Q2 FY24 30 Jun 2024	Q1 FY24 31 Mar 2024	Q4 FY23 31 Dec 2023	Q3 FY23 30 Sept 2023	Q2 FY23 30 Jun 2023	Q1 FY23 31 Mar 2023	Q4 FY22 31 Dec 2022	Q3 FY22 30 Sept 2022	Q2 FY22 30 Jun 2022	Q1 FY22 31 Mar 2022	Q4 FY21 31 Dec 2021	Q3 FY21 30 Sept 2021
Revenues																0	0		598,000*	0
Revenues	0	0	0*	0	0	0	0*	0	0	0	0*	0	0	0				298,500
Cost of revenues											0*	0	0	0	296,000*	0	0	222,000	448,000*	0
Gross profit											0*	0	0	0	64,000*	0	0	76,500	150,000*	0
General and administrative	17,554	60,271	16,377*	115,099	13,614	8,934	9,468*	9,106	9,086	10,298	17,401*	700,150	1,316,425	1,483,566	1,477,894*	1,490,823	1,476,432	1,485,088	1,482,611*	867,206
Total operating expenses	17,554	60,271	16,377*	115,099	13,614	8,934	9,468*	9,106	9,086	10,298	17,401*	1,588,700	3,194,700	4,003,566	3,997,894*	4,010,823	3,996,432	4,005,088	4,002,611*	2,990,656
Research and development							0*	0	0	0	0*	396,550	1,878,275	2,520,000	2,520,000*	2,520,000	2,520,000			2,123,450
Loss from operations	-17,554	-60,271	-16,377*	-115,099	-13,614	-8,934	-9,468*	-9,106	-9,086	-10,298	-17,401*	-1,588,700	-3,194,700	-4,003,566	-3,933,894*	-4,010,823	-3,996,432	-3,928,588	-3,852,611*	-2,990,656
Provision for doubtful accounts							0*	0
Research And Development																		2,520,000
Provision for purchase deposit write-off								0
Provision for doubtful accounts											0*	480,000
Liability extinguishment		20,000
Liability forgiveness	0
Provision for purchase deposit write-off											0*	12,000
Total other expenses				2,710	1,948	1,367	1,205*	1,123	1,057	954	839*	790
Interest expense - related parties	-3,802	-3,503	-3,129*	-2,710	-1,948	-1,367			-1,057
Total other income (expense)	-3,802	16,497
Interest expense - related party															787*	499	211	209	202*	178
Net loss	-21,356	-43,774	42,526*	-117,809	-15,562	-10,301	-10,673*	-10,229	-10,143	-11,252	-18,240*	-1,589,490	-3,195,489	-4,004,354	-3,934,681*	-4,011,322	-3,996,643	-3,928,797	-3,852,813*	-2,990,834
Loss before income tax expense			42,526*	-117,809	-15,562	-10,301	-10,673*	-10,229	-10,143	-11,252	-18,240*	-1,589,490	-3,195,489	-4,004,354		-4,011,322	-3,996,643
Interest expense - related party														788
Interest expense - related parties							1,205*	1,123		954
Total other expenses													789	788	787*	499	211	209	202*	178
Income tax expense			0*	0	0	0	0*	0	0	0	0*	0	0	0			0
Basic and diluted loss per share of common stock	0	-0		0	0	0		-0	-0	-0		-0.03
Loss before income tax credit																			-3,852,813*	-2,990,834
Loss Before Income Tax Credit																		-3,928,797
Interest expense - related party												790	789
Weighted average number of shares of common stock outstanding	60,042,000	60,042,000		60,042,000	60,042,000	60,042,000		60,042,000	60,042,000	60,042,000		60,042,000
Income Taxes Credit																		0	0*	0
Income taxes credit from prior period																0
Basic and diluted loss per share of common stock																				-0.05
Basic And Diluted Loss Per Share Of Common Stock																		-0.07
Basic and diluted loss per share of common stock														-0.07		-0.07	-0.07
Basic and diluted loss per share of common stock													-0.05
Weighted average number of shares of common stock outstanding																				56,870,065
Weighted average number of shares of common stock outstanding														60,042,000		60,042,000	60,042,000	60,042,000
Weighted average number of shares of common stock outstanding													60,042,000